Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Authors: Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Weiping Liu, Jianping Wang, Michele Kosh, NamPhuong Tran, Robin Carson, Pieter Sonneveld

Published: 2023-10-02

DOI: 10.1016/s2352-3026(23)00218-1

Source: Full article

---

Abstract

No abstract found.